TY - JOUR T1 - Retrospective study of treatment outcomes according to exon difference with EGFR mutations in non-small cell lung cancer patient in Korea JF - European Respiratory Journal JO - Eur Respir J VL - 40 IS - Suppl 56 SP - P4205 AU - Ho Sung Lee AU - Jae Sung Choi AU - Ki Hyun Seo AU - Ju Ock Na AU - Yong Hoon Kim AU - Mi Hye Oh AU - Sung Shick Jou Y1 - 2012/09/01 UR - http://erj.ersjournals.com/content/40/Suppl_56/P4205.abstract N2 - Background/Aims: EGFR mutations in NSCLCs are most important biomarker for EGFR-TKI treatment. About 90% of EGFR mutations are clustered in exons 19 (deletion) and 21 (point mutation at codon 858) and patients with these mutations have great response to EGFR-TKIs. However, the response rates of NSCLC to EGFR-TKIs according to types of EGFR mutation in Korea are still not cleared. This study aimed to evaluate the genomic types of EGFR mutation and compare the influence of each genomic types on the response to EGFR-TKIs and clinical outcomes in patients with NSCLC. Methods: We reviewed medical records from January 2007 to August 2011, and classified genotypes of EGFR mutations which were done by direct sequencing methods. Mutation status was compared with clinicopathological features. Clinical outcomes were assessed based on EGFR genotypes. Results: EGFR gene mutations were identified in 43(20.2%) out of 211 NSCLC patients. EGFR mutations were significantly more frequent in females than in males (37.1% vs. 13.4%, p < 0.001), but not correlated with smoking status (22.% vs. 18.1%, p = 0.311). There are no significant differences between exon 19 deletion and exon 21 point mutation at cordon 858 in progression-free survival (10.9 vs. 9.1 months; p = 0.554), nor in overall survival (21.8 vs. 18.2 months; p = 0.142) and disease control rate (90% vs 85.7%; p = 0.669) with EGFR-TKI treatment. Conclusion: PFS and overall survival were not significantly different between exon 19 deletions and Exon 21 L858R mutations, these results are similar to those of previous studies. ER -